Crizotinib-Induced Severe Photosensitive Dermatitis in a Carcinoma Lung Patient

Afra, T. P.; Nair, P; Thanseer, N. T. K.; Razmi, T Muhammed

doi:10.4103/idoj.idoj_291_20

Cited by 2 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 The literature search retrieved seven published cases that were not identified in FAERS and met the inclusion criteria. [3][4][5][6][7][8][9] This resulted in a combined FAERS and literature case series of 18 unique cases of photosensitivity associated with brigatinib, ceritinib, and crizotinib. We did not identify any report of photosensitivity with lorlatinib that met our case definition.…”

Section: Photosensitivity Associated With Anaplastic Lymphoma Kinase ...mentioning

confidence: 99%

Photosensitivity associated with anaplastic lymphoma kinase inhibitors: A review of postmarketing cases reported toFDAand published in the literature

Cheng

Nayernama

Jones

et al. 2022

Photoderm Photoimm Photomed

View full text Add to dashboard Cite

Section: Photosensitivity Associated With Anaplastic Lymphoma Kinase ...mentioning

confidence: 99%

Photosensitivity associated with anaplastic lymphoma kinase inhibitors: A review of postmarketing cases reported toFDAand published in the literature

Cheng

Nayernama

Jones

et al. 2022

Photoderm Photoimm Photomed

View full text Add to dashboard Cite

Overcoming Chemoresistance in Cancer: The Promise of Crizotinib

Musa,

Amara,

Selawi

et al. 2024

Cancers

View full text Add to dashboard Cite

Chemoresistance is a major obstacle in cancer treatment, often leading to disease progression and poor outcomes. It arises through various mechanisms such as genetic mutations, drug efflux pumps, enhanced DNA repair, and changes in the tumor microenvironment. These processes allow cancer cells to survive despite chemotherapy, underscoring the need for new strategies to overcome resistance and improve treatment efficacy. Crizotinib, a first-generation multi-target kinase inhibitor, is approved by the FDA for the treatment of ALK-positive or ROS1-positive non-small cell lung cancer (NSCLC), refractory inflammatory (ALK)-positive myofibroblastic tumors (IMTs) and relapsed/refractory ALK-positive anaplastic large cell lymphoma (ALCL). Crizotinib exists in two enantiomeric forms: (R)-crizotinib and its mirror image, (S)-crizotinib. It is assumed that the R-isomer is responsible for the carrying out various processes reviewed here The S-isomer, on the other hand, shows a strong inhibition of MTH1, an enzyme important for DNA repair mechanisms. Studies have shown that crizotinib is an effective multi-kinase inhibitor targeting various kinases such as c-Met, native/T315I Bcr/Abl, and JAK2. Its mechanism of action involves the competitive inhibition of ATP binding and allosteric inhibition, particularly at Bcr/Abl. Crizotinib showed synergistic effects when combined with the poly ADP ribose polymerase inhibitor (PARP), especially in ovarian cancer harboring BRCA gene mutations. In addition, crizotinib targets a critical vulnerability in many p53-mutated cancers. Unlike its wild-type counterpart, the p53 mutant promotes cancer cell survival. Crizotinib can cause the degradation of the p53 mutant, sensitizing these cancer cells to DNA-damaging substances and triggering apoptosis. Interestingly, other reports demonstrated that crizotinib exhibits anti-bacterial activity, targeting Gram-positive bacteria. Also, it is active against drug-resistant strains. In summary, crizotinib exerts anti-tumor effects through several mechanisms, including the inhibition of kinases and the restoration of drug sensitivity. The potential of crizotinib in combination therapies is emphasized, particularly in cancers with a high prevalence of the p53 mutant, such as triple-negative breast cancer (TNBC) and high-grade serous ovarian cancer (HGSOC).

show abstract

Crizotinib-Induced Severe Photosensitive Dermatitis in a Carcinoma Lung Patient

Cited by 2 publications

References 4 publications

Photosensitivity associated with anaplastic lymphoma kinase inhibitors: A review of postmarketing cases reported toFDAand published in the literature

Photosensitivity associated with anaplastic lymphoma kinase inhibitors: A review of postmarketing cases reported toFDAand published in the literature

Overcoming Chemoresistance in Cancer: The Promise of Crizotinib

Contact Info

Product

Resources

About